{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T22:06:56Z","timestamp":1759702016472},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,10,28]],"date-time":"2005-10-28T00:00:00Z","timestamp":1130457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Objectives.\u2002<\/jats:bold> We aimed to characterize the clinical experiences of patients in whom heparin\u2010induced thrombocytopenia (HIT) complicated heparin therapy for venous thromboembolism (VTE) and who switched to argatroban.<\/jats:p><jats:p><jats:bold>Design.\u2002<\/jats:bold> A retrospective analysis of previously reported prospective, multicentre, historical\u2010controlled Argatroban\u2010911 and Argatroban\u2010915 studies of argatroban therapy in HIT.<\/jats:p><jats:p><jats:bold>Setting.\u2002<\/jats:bold> Inpatient.<\/jats:p><jats:p><jats:bold>Subjects.\u2002<\/jats:bold> Patients (<jats:italic>n<\/jats:italic>\u2003=\u2003145) administered heparin for VTE and who developed HIT were identified.<\/jats:p><jats:p><jats:bold>Interventions.\u2002<\/jats:bold> Patients were treated with argatroban 2\u2003mcg\u2003kg<jats:sup>\u22121<\/jats:sup>\u2003min<jats:sup>\u22121<\/jats:sup> for up to 14\u2003days, adjusted to maintain activated partial thromboplastin times 1.5 to three times baseline. Patient characteristics, anticoagulation and outcomes were summarized. The primary end\u2010point was a composite of death, amputation, or new thrombosis within 37\u2003days of argatroban initiation.<\/jats:p><jats:p><jats:bold>Results.\u2002<\/jats:bold> During heparin therapy, platelet counts decreased (mean\u2003\u00b1\u2003SD nadir: 78\u2003\u00b1\u200367\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\u2003L<jats:sup>\u22121<\/jats:sup>), and 75 (52%) patients developed thrombosis. After heparin was discontinued, patients received argatroban (mean dose 2.1\u2003\u00b1 1.2\u2003mcg\u2003kg<jats:sup>\u22121<\/jats:sup>\u2003min<jats:sup>\u22121<\/jats:sup>) for 6.8\u2003\u00b1\u20034.3\u2003days. By day 6 of argatroban therapy, the mean platelet count rose to &gt;150\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\u2003L<jats:sup>\u22121<\/jats:sup>. The primary end\u2010point occurred in 41 (28.3%) patients (values of 26\u201344% are reported for argatroban therapy of HIT from any heparin indication). Seventeen (11.7%) patients, including 12 who had also experienced thrombosis whilst on heparin, developed new thrombosis after argatroban initiation, typically on the day argatroban was discontinued or later (<jats:italic>n<\/jats:italic>\u2003=\u200310). Seven (4.8%) patients experienced major bleeding.<\/jats:p><jats:p><jats:bold>Conclusions.\u2002<\/jats:bold> For VTE patients with HIT, argatroban provides effective anticoagulation, with outcomes comparable with those reported for other argatroban\u2010treated HIT patients. New thrombosis in this setting occurred most often in patients with existing HIT\u2010associated thrombosis, before HIT recognition or either at\/after argatroban discontinuation.<\/jats:p>","DOI":"10.1111\/j.1365-2796.2005.01573.x","type":"journal-article","created":{"date-parts":[[2005,10,28]],"date-time":"2005-10-28T16:08:15Z","timestamp":1130515695000},"page":"563-572","source":"Crossref","is-referenced-by-count":14,"title":["Heparin\u2010induced thrombocytopenia from venous thromboembolism treatment"],"prefix":"10.1111","volume":"258","author":[{"given":"S. M.","family":"BEGELMAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"HURSTING","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. V.","family":"AGHABABIAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"MCCOLLUM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,11,14]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.12.2212"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.401S"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322003"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1703"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(03)00769-9"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(87)90155-1"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03687.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103013440902"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91054-C"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.4.361"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.311S"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.14.1838"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.15.1849"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-9-199711010-00005"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.18.1961"},{"key":"e_1_2_8_17_2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.5858\/2002-126-1415-PCMALT","article-title":"Platelet count monitoring and laboratory testing for heparin\u2010induced thrombocytopenia: recommendations of the College of American Pathologists","volume":"126","author":"Warkentin TE.","year":"2002","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2004.06.004"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.1.73"},{"key":"e_1_2_8_20_2","first-page":"397","volume-title":"Heparin\u2010induced Thrombocytopenia","author":"Greinacher A.","year":"2004"},{"key":"e_1_2_8_21_2","first-page":"371","volume-title":"Heparin\u2010induced Thrombocytopenia","author":"Chong BH","year":"2004"},{"key":"e_1_2_8_22_2","first-page":"537a","article-title":"Bivalirudin treatment of heparin\u2010induced thrombocytopenia (abstract)","volume":"102","author":"Berilgen JE","year":"2003","journal-title":"Blood"},{"key":"e_1_2_8_23_2","first-page":"1017","article-title":"Treatment of heparin\u2010induced thrombocytopenia with fondaparinux","volume":"89","author":"Harenberg J","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-1-199607010-00001"},{"key":"e_1_2_8_25_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0037-1615601","article-title":"Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin","volume":"85","author":"Sheth SB","year":"2001","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH03-12-0794"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-2010"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.20.2260"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2005.01573.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2796.2005.01573.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T15:23:51Z","timestamp":1697124231000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2005.01573.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,14]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1365-2796.2005.01573.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2005.01573.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,14]]}}}